HEADLYS FARM LLP.

01/11/2026

01/10/2026

01/10/2026

01/01/2026

Happy New Year Everyone! 🎉

12/31/2025

12/28/2025

12/19/2025

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.

12/19/2025

🌿 "The Administration's order calling to remove the cannabis plant from its Schedule I classification validates the experiences of tens of millions of Americans, as well as those of tens of thousands of physicians, who have long recognized that cannabis possesses legitimate medical utility," said NORML Deputy Director Paul Armentano. "It wasn’t long ago that federal officials were threatening to seize doctors’ medical licenses just for discussing medical cannabis with their patients. This directive certainly marks a long overdue change in direction."

Read more: https://norml.org/blog/2025/12/18/president-trump-takes-executive-action-to-federally-reschedule-marijuana/

11/24/2025

11/24/2025

Overwhelming majority were simple possession

11/12/2025

There’s an unexpected consequence inside the deal to end the federal government shutdown: making h**p products illegal. As part of the Senate compromise to end the shutdown, THC would be limited to 0.4 milligrams per container.

The H**p Industry & Farmers of America said in a statement that the Senate ban could result in the “devastation of an entire industry,” noting that the provision would “ban Delta-8 products, THCA flower, and virtually all h**p-derived cannabinoid products.”

Bob Galligan, director of government and industry relations for the Minnesota Craft Brewers Guild, is a lobbyist for well over 100 Minnesota craft breweries, most of which, he said, have turned to THC as consumers drink less alcohol.

“The language as it stands right now, if it were to go through, decimation is a pretty accurate word,” he said.